Medical/Pharmaceuticals
Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease
SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. SKY-0515's Phase 1 study will include healthy volunteers before targetingHuntington's patients. Huntington's disease is a fatal neurological disease with no curative therapies. WALTHAM, Ma...
2023-10-23 20:00
1883
The team from Kelun-Biotech held a meeting with representatives from MSD in Madrid, Spain
CHENGDU, China, Oct. 23, 2023 /PRNewswire/ -- On October 20, 2023, the European Society for Medical Oncology (ESMO) Conference grandly commenced inMadrid, Spain . The ESMO Conference is the most esteemed and influential oncology conference inEurope, and this annual event garners the participation ...
2023-10-23 18:16
3552
Global Healthcare Accreditation Welcomes Karin Jay as President of Global Strategy and Announces Renée-Marie Stephano's Transition to CEO
New Leadership Aims to Reinforce GHA's Position as the Foremost Authority in Medical and Well-being Travel Accreditation PALM BEACH GARDENS, Fla., Oct. 23, 2023 /PRNewswire/ -- Global Healthcare Accreditation (GHA), the esteemed authority in accreditation and certification with a specialized foc...
2023-10-23 18:00
1897
Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care
SHENZHEN, China, Oct. 23, 2023 /PRNewswire/ -- Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascu...
2023-10-23 17:53
4172
Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023
* HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials inAustralia, targeting multiple solid tumors * The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe treatment-re...
2023-10-23 14:23
2643
Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at JSA2023
TOKYO, Oct. 23, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a biotech company specializing in the development of treatments for allergy, asthma, nephrology, dermatology, ophthalmology and other autoimmune diseases, oral presented the phase I data of ...
2023-10-23 12:27
3255
EBR Systems nominated for MTAA Excellence in Medical Technology award
SUNNYVALE, Calif., Oct. 23, 2023 /PRNewswire/ -- EBR Systems, Inc. (ASX:EBR),
the developer of the world's only wireless cardiac pacing device for heart
failure, is pleased to announce it has been named as a nominee for the 2023
Medical Technology Association ofAustralia
2023-10-23 12:26
3165
Gene Technology Light Up the Future - Opening of the International Conference of Genomics on Eye 2023
SHENYANG, China, Oct. 21, 2023 /PRNewswire/ -- The International Conference of Genomics on Eye 2023 (the "6th ICG Eye") embraced its grand opening in Shenyang on 14th-15th October. The conference, hosted by the Shenyang Municipal People's Government, organized by the Shenyang Bureau of Science a...
2023-10-21 03:12
4363
Striving Together For A Thriving Industry, International Biopharma Industry Week Shanghai 2023 Opens
SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- On October 16th, the inaugural ceremony of the 2023 International Biopharma Industry Week Shanghai (IBIWS 2023) unfolded at the Zhangjiang Science Hall inShanghai. Spanning five days, this event, themed as "Striving Together for A Thriving Industry," endeav...
2023-10-20 15:29
3600
Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)
Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience's anti-HER3 ADC to be developed for patients with HER3-expressing tumors Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalties, from Endeavor BioMedicines Investigational New Drug ...
2023-10-19 20:18
2900
Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023
JINAN, China, Oct. 19, 2023 /PRNewswire/ -- Data from Qilu Pharmaceutical's clinical trial of its novel bifunctional antibody, QL1706 (iparomlimab and tuvonralimab), will be unveiled during a mini oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress 2023. The ESMO...
2023-10-19 19:42
2857
ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
* The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC) * Preliminary activity demonstrates meaningful PSA[1] reduction; monitoring of patients is ongoing, i...
2023-10-19 06:01
2853
Dr. Huda Zoghbi Reveals New Research Into the Mechanisms Driving Rett Syndrome at the 2023 World Congress of Neurology
MONTREAL, Oct. 19, 2023 /PRNewswire/ -- Huda Zoghbi, MD, professor of molecular and human genetics,Baylor College of Medicine, has made a groundbreaking discovery in the field of neurology. Her research shows that mutations in the MECP2 gene are responsible for causing Rett syndrome, a childhood ...
2023-10-19 01:09
2240
Frost & Sullivan Recognizes Neuromod Devices with the 2023 New Product Innovation Award for Developing a Robust Solution That Meets Tinnitus Patients' Needs
Neuromod Devices uniquely leverages its sophisticated technology to meet tinnitus patients' dynamic needs and strict global regulatory requirements for medical devices. SAN ANTONIO, Oct. 19, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the neuromodulation devices for tinnitus space ...
2023-10-19 01:03
2431
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
BRENTWOOD, Tenn., Oct. 18, 2023 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax") today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the cardiovascular safety of CONTRAVE®/MYSIMBA®, a weight management drug. The real-world study compare...
2023-10-18 20:00
3290
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
GAITHERSBURG, Md., Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced thatSingapore's Health Sciences Authority (HSA) has granted full approval for Novavax's prototype COVID-19 vaccine Nuvaxovi...
2023-10-18 20:00
2560
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science BOSTON and ROLLE, Switzerland, Oct. 18, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in da...
2023-10-18 20:00
2787
Seegene Reinforces Commitment to Strong ESG Management with 100% Recyclable, Styrofoam-Free Shipping Boxes
* 100% recyclable package made with eco-friendly and FSC-certified materials to proactively meet evolving global environmental regulations * Patent design provides a 30% increase in load capacity and an up to 52% reduction in transportation costs * This initiative is part of Seegene's effort...
2023-10-18 19:00
3165
Telix reports fourth consecutive quarter of positive operating cash flow
MELBOURNE, Australia, Oct. 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise s...
2023-10-18 15:42
2590
Yuyu Pharma to attend 'CPHI Worldwide 2023'
SEOUL, South Korea, Oct. 18, 2023 /PRNewswire/ -- Yuyu Pharma will be attending
CPHI Worldwide inBarcelona, Spain from October 24th to October 26th.
2023-10-18 15:00
7449
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Taishin International Bank Opens Flagship Private Banking Branch in Southern Taiwan
[Picked up by 270 media titles]
2026-10-23 19:08
Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
34858
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
33008
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
31556
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
27234
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
2026-10-21 15:00
15302